Crystalys Therapeutics

Executive Summary

Crystalys Therapeutics is a private preclinical-stage biotechnology company headquartered in Cambridge, US, that combines artificial intelligence, structural biology, and advanced proteomics to discover novel small molecule drugs for challenging protein targets. Founded in 2021 and having raised $205 million, the company initially focuses on oncology and neurodegenerative diseases. Its platform integrates computational modeling and machine learning to identify and optimize compounds, aiming to address targets that have historically been difficult to drug. As a preclinical entity, Crystalys has not yet advanced any candidate into clinical trials, and its valuation is estimated. The significant funding suggests strong investor confidence in its AI-driven approach, but the company remains in early development with no commercial products or FDA approvals. Key risks include technical validation of its platform and successful translation into clinical candidates.

Upcoming Catalysts (preview)

• Q3 2026Presentation of preclinical data for lead oncology program at a major scientific conference75% success
• Q4 2026Filing of Investigational New Drug (IND) application for lead candidate in oncology40% success
• Q1 2027Announcement of strategic partnership or collaboration with a large pharma company for neuroscience program50% success